{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T03:47:50Z","timestamp":1773028070737,"version":"3.50.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2009,2,25]],"date-time":"2009-02-25T00:00:00Z","timestamp":1235520000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2009,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Advanced pancreatic cancer has a poor prognosis, and the current standard of care (gemcitabine based chemotherapy) provides a small survival advantage. However the drawback is the accompanying systemic toxicity, which targeted treatments may overcome. This study aimed to evaluate the safety and tolerability of KAb201, an anti-carcinoembryonic antigen monoclonal antibody, labelled with I<jats:sup>131<\/jats:sup> in pancreatic cancer (ISRCTN 16857581).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Patients with histological\/cytological proven inoperable adenocarcinoma of the head of pancreas were randomised to receive KAb 201 via either the intra-arterial or intravenous delivery route. The dose limiting toxicities within each group were determined. Patients were assessed for safety and efficacy and followed up until death.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Between February 2003 and July 2005, 25 patients were enrolled. Nineteen patients were randomised, 9 to the intravenous and 10 to the intra-arterial arms. In the intra-arterial arm, dose limiting toxicity was seen in 2\/6 (33%) patients at 50 mCi whereas in the intravenous arm, dose limiting toxicity was noted in 1\/6 patients at 50 mCi, but did not occur at 75 mCi (0\/3).<\/jats:p>\n            <jats:p>The overall response rate was 6% (1\/18). Median overall survival was 5.2 months (95% confidence interval = 3.3 to 9 months), with no significant difference between the intravenous and intra-arterial arms (log rank test p = 0.79). One patient was still alive at the time of this analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Dose limiting toxicity for KAb201 with I<jats:sup>131<\/jats:sup> by the intra-arterial route was 50 mCi, while dose limiting toxicity was not reached in the intravenous arm.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2407-9-66","type":"journal-article","created":{"date-parts":[[2009,2,25]],"date-time":"2009-02-25T19:14:32Z","timestamp":1235589272000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Randomised Phase I\/II trial assessing the safety and efficacy of radiolabelled anti-carcinoembryonic antigen I131KAb201 antibodies given intra-arterially or intravenously in patients with unresectable pancreatic adenocarcinoma"],"prefix":"10.1186","volume":"9","author":[{"given":"Asma","family":"Sultana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susannah","family":"Shore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael GT","family":"Raraty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sobhan","family":"Vinjamuri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan E","family":"Evans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catrin Tudur","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Lane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seema","family":"Chauhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorraine","family":"Bosonnet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Conall","family":"Garvey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Sutton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John P","family":"Neoptolemos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Ghaneh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,2,25]]},"reference":[{"key":"1400_CR1","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/S0959-8049(01)00267-2","volume":"37","author":"D Parkin","year":"2001","unstructured":"Parkin D, Bray F, Devesa S: Cancer burden in the year 2000. The global picture. Eur J Can. 2001, 37: S4-S66. 10.1016\/S0959-8049(01)00267-2.","journal-title":"Eur J Can"},{"key":"1400_CR2","unstructured":"Cancer Stats Incidence. [http:\/\/info.cancerresearchuk.org\/cancerstats]"},{"key":"1400_CR3","unstructured":"Cancer Stat Fact Sheet- Cancer of the pancreas. [http:\/\/seer.cancer.gov\/statfacts\/html\/pancreas.html]"},{"issue":"2","key":"1400_CR4","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3322\/CA.2007.0010","volume":"58","author":"A Jemal","year":"2008","unstructured":"Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics, 2008. CA: a cancer journal for clinicians. 2008, 58 (2): 71-96. 10.3322\/CA.2007.0010.","journal-title":"CA: a cancer journal for clinicians"},{"issue":"11\u201312","key":"1400_CR5","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1111\/j.1365-2036.2003.01781.x","volume":"18","author":"S Shore","year":"2003","unstructured":"Shore S, Raraty M, Ghaneh P, Neoptolemos J: Chemotherapy for pancreatic cancer. Aliment Pharmacol Ther. 2003, 18 (11\u201312): 1049-1069. 10.1111\/j.1365-2036.2003.01781.x.","journal-title":"Aliment Pharmacol Ther"},{"key":"1400_CR6","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","volume":"15","author":"H Burris","year":"1997","unstructured":"Burris H, Moore M, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomised trial. J Clin Oncol. 1997, 15: 2403-2413.","journal-title":"J Clin Oncol"},{"issue":"18","key":"1400_CR7","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1200\/JCO.2006.09.2551","volume":"25","author":"A Sultana","year":"2007","unstructured":"Sultana A, Tudur Smith C, Cunningham D, Starling N, Neoptolemos J, Ghaneh P: Meta-Analyses of Chemotherapy for Locally Advanced and Metastatic Pancreatic Cancer. J Clin Oncol. 2007, 25 (18): 2607-2615. 10.1200\/JCO.2006.09.2551.","journal-title":"J Clin Oncol"},{"key":"1400_CR8","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","volume":"25","author":"MJ Moore","year":"2007","unstructured":"Moore MJ, Goldstein D, Hamm J, et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007, 25: 1960-1966. 10.1200\/JCO.2006.07.9525.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1400_CR9","first-page":"196","volume":"47","author":"R Reilly","year":"2006","unstructured":"Reilly R: Radioimmunotherapy of solid tumors: the promise of pretargeting strategies using bispecific antibodies and radiolabeled haptens. J Nucl Med. 2006, 47 (2): 196-199.","journal-title":"J Nucl Med"},{"key":"1400_CR10","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/1520-6866(2001)21:1<45::AID-TCM5>3.0.CO;2-A","volume":"21","author":"A Goel","year":"2001","unstructured":"Goel A, Batra S: Antibody constructs for radioimmunodiagnosis and treatment of human pancreatic cancer. Teratogenesis, Carcinogenesis, and Mutagenesis. 2001, 21: 45-57. 10.1002\/1520-6866(2001)21:1<45::AID-TCM5>3.0.CO;2-A.","journal-title":"Teratogenesis, Carcinogenesis, and Mutagenesis"},{"issue":"2","key":"1400_CR11","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/0092-8674(89)90970-7","volume":"57","author":"S Benchimol","year":"1989","unstructured":"Benchimol S, Fuks A, Jothy S, Beauchemin N, Shirota K, Stanners C: Carcino-embryonic antigen, a human tumour marker, functions as an intercellular adhesion molecule. Cell. 1989, 57 (2): 327-334. 10.1016\/0092-8674(89)90970-7.","journal-title":"Cell"},{"issue":"1","key":"1400_CR12","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/jnci\/57.1.11","volume":"57","author":"D Goldenberg","year":"1976","unstructured":"Goldenberg D, Sharkey R, Primus F: Carcino-embryonic antigen in histopathology: immunoperoxidase staining of conventional tissue sections. J Natl Cancer Inst. 1976, 57 (1): 11-22.","journal-title":"J Natl Cancer Inst"},{"key":"1400_CR13","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/j.1749-6632.1983.tb32851.x","volume":"417","author":"F Grunert","year":"1983","unstructured":"Grunert F, Luckenbach G, Haderlie B, Schwarz K, von Kleist S: Comparison of colon, lung, and breast-derived carcinoembryonic antigen and cross-reacting antigens by monoclonal antibodies and fingerprint analysis. Ann N Y Acad Sci. 1983, 417: 75-85. 10.1111\/j.1749-6632.1983.tb32851.x.","journal-title":"Ann N Y Acad Sci"},{"issue":"5","key":"1400_CR14","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1200\/JCO.2005.03.8471","volume":"24","author":"D Goldenberg","year":"2006","unstructured":"Goldenberg D, Sharkey R, Paganelli G, Barbet J, Chatal J: Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol. 2006, 24 (5): 823-834. 10.1200\/JCO.2005.03.8471.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1400_CR15","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1038\/nbt1137","volume":"23","author":"G Adams","year":"2005","unstructured":"Adams G, Weiner L: Monoclonal antibody therapy of cancer. Nature Biotechnology. 2005, 23 (9): 1147-1157. 10.1038\/nbt1137.","journal-title":"Nature Biotechnology"},{"issue":"4 Suppl","key":"1400_CR16","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1002\/cncr.10308","volume":"94","author":"T Behr","year":"2002","unstructured":"Behr T, Liersch T, Greiner-Bechert L, Greisinger F, Behe M, Markus P, Gratz S, Angerstein C, Brittinger G, Becker H, et al: Radioimmunotherapy of small-volume disease of metastatic colorectal cancer. Cancer. 2002, 94 (4 Suppl): 1373-1381. 10.1002\/cncr.10308.","journal-title":"Cancer"},{"issue":"10 Suppl","key":"1400_CR17","first-page":"3232s","volume":"5","author":"T Behr","year":"1999","unstructured":"Behr T, Salib A, Liersch T, Behe M, Angerstein C, Blumenthal R, Fayyazi A, Sharkey R, Ringe B, Becker H, et al: Radioimmunotherapy of small volume disease of colorectal cancer metastatic to the liver: preclinical evaluation in comparison to standard chemotherapy and initial results of a phase I clinical study. Clin Cancer Res. 1999, 5 (10 Suppl): 3232s-3242s.","journal-title":"Clin Cancer Res"},{"key":"1400_CR18","first-page":"1125","volume":"45","author":"K Aigner","year":"1998","unstructured":"Aigner K, Gailhoter S, Kopp S: Regional versus systemic chemotherapy for advanced pancreatic cancer: a randomised study. Hepatogastroenterology. 1998, 45: 1125-1129.","journal-title":"Hepatogastroenterology"},{"issue":"9","key":"1400_CR19","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1200\/JCO.2005.03.8166","volume":"24","author":"N Kemeny","year":"2006","unstructured":"Kemeny N, Niedzwiecki D, Hollis D, et al: Hepatic arterial infusion versus sytemic therapy for hepatic metastases from colorectal cancer: a randomised trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol. 2006, 24 (9): 1395-1403. 10.1200\/JCO.2005.03.8166.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1400_CR20","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1002\/jso.2930470303","volume":"47","author":"K Yamaguchi","year":"1991","unstructured":"Yamaguchi K, Enjoji M, Tsuneyoshi M: Pancreatoduodenal carcinoma: a clinicopathologic study of 304 patients and immunohistochemical observation for CEA and CA19-9. J Surg Oncol. 1991, 47 (3): 148-154. 10.1002\/jso.2930470303.","journal-title":"J Surg Oncol"},{"key":"1400_CR21","doi-asserted-by":"publisher","first-page":"231","DOI":"10.2174\/157016306780368108","volume":"3","author":"K Engelhardt","year":"2006","unstructured":"Engelhardt K, Riley C, Cooke L, Mahadevan D: Monoclonal antibody therapies targeting pancreatic ductal adenocarcinoma. Current Drug Discovery Technologies. 2006, 3: 231-243. 10.2174\/157016306780368108.","journal-title":"Current Drug Discovery Technologies"},{"issue":"6","key":"1400_CR22","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.surg.2005.02.002","volume":"137","author":"JY Mabrut","year":"2005","unstructured":"Mabrut JY, Fernandez-Cruz L, Azagra JS, Bassi C, Delvaux G, Weerts J, Fabre JM, Boulez J, Baulieux J, Peix JL, et al: Laparoscopic pancreatic resection: results of a multicenter European study of 127 patients. Surgery. 2005, 137 (6): 597-605. 10.1016\/j.surg.2005.02.002.","journal-title":"Surgery"},{"issue":"2","key":"1400_CR23","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1089\/hyb.1999.18.183","volume":"18","author":"J Osborne","year":"1999","unstructured":"Osborne J, Harrison P, Butcher R, Ebsworth N, Tan K: Novel super-high affinity sheep monoclonal antibodies against CEA bind colon and lung adenocarcinoma. Hybridoma. 1999, 18 (2): 183-191.","journal-title":"Hybridoma"},{"key":"1400_CR24","first-page":"29","volume-title":"Xenova Biomedix","author":"Investigator brochure","year":"2004","unstructured":"Investigator brochure: Anti-CEA monoclonal antibody KAb 201 radiolabelled with 131 Iodine. Xenova Biomedix. 2004, 29-31."},{"issue":"4","key":"1400_CR25","first-page":"43","volume":"19","author":"S Vinjamuri","year":"2004","unstructured":"Vinjamuri S, Sultana A, Shore S, Ghaneh P, Neoptolemos J: Feasibility of using iodine-131 labelled super-high affinity chimaeric antibody targeted against CEA in patients with pancreatic cancer. Cancer Biotherapy and Radiopharmaceuticals. 2004, 19 (4): 43-","journal-title":"Cancer Biotherapy and Radiopharmaceuticals"},{"issue":"3","key":"1400_CR26","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck S, Eisenhauer E, et al: New Guidelines to evaluate the response to treatment in solid tumours. Journal of the National Cancer Institute. 2000, 92 (3): 205-216. 10.1093\/jnci\/92.3.205.","journal-title":"Journal of the National Cancer Institute"},{"key":"1400_CR27","unstructured":"Cancer Therapy Evaluation Program CTCAE\/CTC Archive. [http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_archive]"},{"key":"1400_CR28","volume-title":"Methods in observational epidemiology","author":"J Kelsey","year":"1996","unstructured":"Kelsey J, Whittemore A, Evans A, Thompson W: Methods in observational epidemiology. 1996, New York: Oxford University Press, 2","edition":"2"},{"issue":"1","key":"1400_CR29","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3816\/CCC.2002.n.009","volume":"2","author":"G Hajjar","year":"2002","unstructured":"Hajjar G, Sharkey R, Burton J, et al: Phase I radioimmunotherapy trial with iodine-131-babeled humanised MN-14 anti-carcinoembryonic antigen monoclonal antibody in patients with metastatic gastrointestinal and colorectal cancer. Clin Colorectal Cancer. 2002, 2 (1): 31-42. 10.3816\/CCC.2002.n.009.","journal-title":"Clin Colorectal Cancer"},{"key":"1400_CR30","unstructured":"Knox S, Goris M, Tempero M, Weiden P, Gentner L, Breitz H, Adams G, Axworthy D, Gaffigan S, Bryan K, et al: Phase II trial of Yttrium-90-DOTA-Biotin Pretargeted by NR-LU-10 Antibody\/Streptavidin in patients with metastatic colon cancer. Clinical Cancer Research. 2000, 406-414. 6"},{"issue":"6","key":"1400_CR31","first-page":"858","volume":"38","author":"TM Behr","year":"1997","unstructured":"Behr TM, Sharkey RM, Juweid ME, et al: Phase I\/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG. J Nucl Med. 1997, 38 (6): 858-870.","journal-title":"J Nucl Med"},{"issue":"1","key":"1400_CR32","first-page":"34","volume":"39","author":"M Juweid","year":"1998","unstructured":"Juweid M, Sharkey RM, Swayne LC, Griffiths GL, Dunn R, Goldenberg D: Pharmacokinetics, dosimetry and toxicity of rhenium-188-labeled anti-carcinoembryonic antigen monoclonal antibody, MN-14, in gastrointestinal cancer. The Journal of Nuclear Medicine. 1998, 39 (1): 34-42.","journal-title":"The Journal of Nuclear Medicine"},{"issue":"18","key":"1400_CR33","first-page":"6851","volume":"61","author":"G Ritter","year":"2001","unstructured":"Ritter G, Cohen L, Williams CJ, Richards EC, Old LJ, Welt S: Serological analysis of human anti-human responses in colon cancer patients treated with repeated doses of humanised monoclonal antibody A33. Cancer Res. 2001, 61 (18): 6851-6859.","journal-title":"Cancer Res"},{"key":"1400_CR34","volume-title":"Eur J Can","author":"D Cunningham","year":"2005","unstructured":"Cunningham D, Chau I, Stocken D, et al: Phase III randomised comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. Eur J Can. 2005, 4: Abstract PS11"},{"issue":"4","key":"1400_CR35","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/BF00047468","volume":"6","author":"R Jain","year":"1987","unstructured":"Jain R: Transport of molecules across tumor vasculature. Cancer Metastasis Rev. 1987, 6 (4): 559-593. 10.1007\/BF00047468.","journal-title":"Cancer Metastasis Rev"},{"issue":"5","key":"1400_CR36","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/BF03027399","volume":"19","author":"N Oriuchi","year":"2005","unstructured":"Oriuchi N, Higuchi T, Hanaoka H, Iida Y, Endo K: Current status of cancer therapy with radiolabeled monoclonal antibody. Annals of Nuclear Medicine. 2005, 19 (5): 355-365. 10.1007\/BF03027399.","journal-title":"Annals of Nuclear Medicine"},{"issue":"15","key":"1400_CR37","doi-asserted-by":"publisher","first-page":"3270","DOI":"10.1200\/JCO.2002.11.149","volume":"20","author":"JD Berlin","year":"2002","unstructured":"Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson AB: Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol. 2002, 20 (15): 3270-3275. 10.1200\/JCO.2002.11.149.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1400_CR38","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1002\/cncr.10323","volume":"94","author":"G Colucci","year":"2002","unstructured":"Colucci G, Guiliani F, Gebbia V, et al: Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and\/or metastatic pancreatic carcinoma. Cancer. 2002, 94 (4): 902-910. 10.1002\/cncr.10323.","journal-title":"Cancer"},{"key":"1400_CR39","volume-title":"ASCO Annual Meeting: 2005","author":"H Reiss","year":"2005","unstructured":"Reiss H, Helm A, Niedergethmann M, Schmidt-Wolf I, Moik M, Hammer C, Zippel K, Weigang-Kohler K, Stauch M, Oettle H: A randomised, prospective, multicentre, phase III trial of gemcitabine, 5-Fluorouracil, folinic acid versus gemcitabine alone in patients with advanced pancreatic cancer. ASCO Annual Meeting: 2005. 2005, abstract no LBA4009."},{"key":"1400_CR40","volume-title":"2005 ASCO Annual Meeting: 2005; Orlando, USA","author":"R Hermann","year":"2005","unstructured":"Hermann R, Bodoky G, Ruhstaller T, Glimelius B, Saletti P, Bajetta E, Schueller J, Bernhard J, Dietrich D, Scheithauer W: Gemcitabine plus capecitabine versus gemcitabine alone in locally advanced or metastatic pancreatic cancer. A randomised phase III study of the Swiss Group for Clinical Cancer Research (SAKK) and the Central European Cooperative Oncology Group (CECOG). 2005 ASCO Annual Meeting: 2005; Orlando, USA. 2005, Abstract no LBA4010."},{"issue":"24","key":"1400_CR41","doi-asserted-by":"publisher","first-page":"3946","DOI":"10.1200\/JCO.2005.05.1490","volume":"24","author":"V Heinemann","year":"2006","unstructured":"Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, et al: Randomised phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol. 2006, 24 (24): 3946-3952. 10.1200\/JCO.2005.05.1490.","journal-title":"J Clin Oncol"},{"key":"1400_CR42","first-page":"247","volume":"47","author":"F Kraeber-Bodere","year":"2006","unstructured":"Kraeber-Bodere F, Rousseau C, Bodet-Milin C, et al: Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimisation clinical trial. J Nucl Med. 2006, 47: 247-255.","journal-title":"J Nucl Med"},{"key":"1400_CR43","first-page":"248","volume":"50","author":"D Goldenberg","year":"2006","unstructured":"Goldenberg D, Sharkey RM: Advances in cancer therapy with radiolabeled monoclonal antibodies. Q J Nuclear Med Mol Imaging. 2006, 50: 248-264.","journal-title":"Q J Nuclear Med Mol Imaging"},{"key":"1400_CR44","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1002\/ijc.20004","volume":"109","author":"D Gold","year":"2004","unstructured":"Gold D, Modrak D, Schutsky K, Cardillo T: Combined 90Yttrium-dota-labeled PAM4 antibody radioimmunotherapy and gemcitabine radiosensitization for the treatment of a human pancreatic cancer xenograft. Int J Cancer. 2004, 109: 618-628. 10.1002\/ijc.20004.","journal-title":"Int J Cancer"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-9-66.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-9-66\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-9-66","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-9-66.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T10:38:12Z","timestamp":1630492692000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-9-66"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2,25]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["1400"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-9-66","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,2,25]]},"assertion":[{"value":"21 July 2008","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2009","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2009","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"66"}}